Comparación de la prescripción-indicación de  carbapenems en niños en la Unidad de Cuidados  Intensivos de Pediatría del Hospital Roosevelt

G. Arévalo-Marini

doi:10.54495/Rev.Cientifica.v25i1.95

Authors

G. Arévalo-Marini Escuela de Química Farmacéutica, Universidad de San Carlos de Guatemala

DOI:

https://doi.org/10.54495/Rev.Cientifica.v25i1.95

Keywords:

Carbapenems, Pediatric Intensive Care Unit, nosocomial infections, sepsis, Roosevelt Hospital

Abstract

The carbapenem are considered restricted antibiotics, use either alone or in combination with vancomycin. There are among the most effective antimicrobial treatments against multidrog resistant infections. To indicate them, bring strict control of potencial interactions and adverse effects, for prevent hepatic and renal disfunction. It should be previos culture (sensitivity test) the indication to prevent antimicrobian resistance. The use of orotracheal tubes and staying longer than 5 days in the service, are risk factors for acquiring a nosocomial infection. Roosevelt Hospital in many cases of bacteria resistant to several antibiotics were reported (unpublished datas). The objective of this studio was to collect information about the use of the carbapenems, because there is no standard protocol for use in the Standards for the prevention and control of infection associated with health care, of nosocomial infection committee, of Roosevelt Hospital. The information generated will be useful in other investigations to determinate, test or verify new methods or already established, for others after diagnosis, may indicate a carbapenem for the antimicrobial treatment to be effective, either for an infection in the community or nosocomial.

Downloads

Download data is not yet available.

References

Europe Pubmed Central (2011). Performance Evaluation of VITEK 2 System in Meropenem Susceptibility Testing of Clinical Pseudomonas aeruginosa Isolates. Turkey: Yeditepe University Faculty of Medicine, Department of Medical Microbiology, 45(3), 411-421. Recuperado de http://www.europepmc/abstract/med/21935774

Ayestarán, X., Molina, A., Oliver, O., Delgado, F. (2010). Revisión de Carbapenems. Informe para la Comisión de Infección Hospitalaria del Hospital Universitario Son Dureta. Palma de Mallorca, Islas Baleares, España.

Clarkson, M., Friedewald, J., Eustace, J., Rabb, H. (2008). Acute kidney injury. In: Brenner BM, Brenner and Rector’s (Ed), The Kidney. (8th ed. Philadelphia, Chap. 29). Nederland: Saunders Elsevier. https://doi.org/10.1038/ki.2008.117 DOI: https://doi.org/10.1038/ki.2008.117

Comité de Expertos en la Selección y Uso de Medicamentos Esenciales, (2008). Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. (29 September to 3 October 2008). Geneva, Switzerland.

Curcio, D. y Alí, A. y Duarte, A. (2009). Prescription of antibiotics in intensive care units in Latin America: an observational study. Journal of Chemotherapy. 21(5), 527-534. https://doi.org/10.1179/joc.2009.21.5.527 DOI: https://doi.org/10.1179/joc.2009.21.5.527

Díaz, R. (2011). Impacto de las infecciones nosocomiales y de la resistencia bacteriana en Unidad de Cuidados Intensivos. Revista Electrónica de Medicina Intensiva. 11(3), 1608. Recuperado de http://remi.uninet.edu/2011/03/REMI1608.html

García, C. (2003). Resistencia bacteriana en Chile. Revista chilena de infectología, 20(1),11-23. https://doi.org/10.4067/S0716-10182003020100002 DOI: https://doi.org/10.4067/S0716-10182003020100002

Giner, S. y Canós, M. (1995). Meropenem: Un nuevo carbapenem en el arsenal terapéutico. Sección de Microbiología, Hospital Virgen de los Lirios. España. Ed. Técnica.

Gómez, B. (2011). Uso de Carbapenems en el Hospital Escuela “Dr. Antonio Lenin Fonseca” de junio a noviembre del 2010.

Nicaragua. Katzung, G. (2005). Farmacología básica y clínica. (9na. ed.), México: Ed. El Manual Moderno. 743-744, 764.

Landry, D., Bazari, H. (2011). Approach to the patient with renal disease. In: Goldman L, Schafer AI, (Ed), Cecil Medicine. (24th ed. Philadelphia, 116). Nederland: Saunders Elsevier.

Limdi, J., Hyde, G. (2003). Evaluación de las Pruebas de Función Hepática Anormales. Evaluation of Abnormal Liver Function Tests Magazine. Postgraduate Medical Journal, 79,(932), 307-312. https://doi.org/10.1136/pmj.79.932.307 DOI: https://doi.org/10.1136/pmj.79.932.307

Martínez, J., Aguilar, J., Almela, M., Marco, F., Soriano, A., López, F., Balasso, V., Pozo L. & Mensa, J. (2006). Prior use of carbapenems may be a significant risk factor for extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. Oxford University Press. https://doi.org/10.1093/jac/dkl367 DOI: https://doi.org/10.1093/jac/dkl367

Mejía, C. y Silvestre, M. (2008). Normas de Prevención y Control de Infecciones Asociadas a Cuidados de la Salud, Nosocomiales. Guatemala: Comité de Infecciones Nosocomiales. Hospital Roosevelt.

Sánchez, L., Sáenz, E., Pancorbo, J., Lanchipa, P., Zegarra, R. (2004). A ntibióticos Sistémicos en Dermatología. Primera parte: Betalactámicos: Carbapenems, Aminoglucósidos, Macrolidos. Educación médica continúa. Dermatología Peruana, 14(1): 12-13. Recuperado de http://www.sisbib.unmsm.edu.pe/bvrevistas/dermatologia/v14_n1/contenido.htm